Objectives-To investigate whether the intrinsic subtypes of breast cancers initially assessed as American College of Radiology Breast Imaging and Reporting System (BI-RADS) category 3 or 4a differ according to tumor size.
B
reast cancers can be classified into distinct entities called intrinsic subtypes based on messenger RNA expression data such as the luminal A, B, human epidermal growth factor receptor 2 (HER2)-enriched, and basal-like subtypes. 1 Although basal-like breast cancer is not exactly synonymous with triple-negative breast cancer, the terms are clinically used interchangeably because breast cancers can be categorized into 3 therapeutic groups according to expression of the hormonal receptor or HER2. [2] [3] [4] [5] Breast cancers have different prognoses according to their subtypes, and the triple-negative subtype is known to have poorer prognosis and more aggressive clinical behavior than the luminal subtype. 6, 7 Previous studies have shown that imaging features differ according to the intrinsic subtype. [8] [9] [10] [11] [12] [13] [14] [15] Although the expected malignancy rates are less than 2% and 10% for American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) category 3 and 4a lesions, respectively, 16 triple-negative breast cancers can also appear benign like on ultrasonography (US), so they can be overlooked as benign. 13, 17 Breast cancer size is an important factor that affects the prognosis, and larger cancers have a worse prognosis than smaller cancers. 6, 18, 19 Previous research found that initially detected breast cancers had tumor sizes that varied according to the intrinsic subtype and that the triple-negative subtype was more frequently observed in larger tumors. 9, 11, 20, 21 To our knowledge, no study has focused on how the intrinsic subtype differs according to tumor size, especially in breast cancers with more benign imaging features. The aim of this study was to investigate whether the intrinsic subtypes of breast cancers initially assessed as BI-RADS category 3 or 4a differed according to tumor size.
Materials and Methods
The Institutional Review Board approved this retrospective study and required neither patient approval nor informed consent for our review of patient images and records.
Study Population
From January 2005 to December 2015, 20,232 coreneedle biopsies were performed in our institution. Each biopsied lesion was analyzed at the time of core needle biopsy and had its BI-RADS category evaluated. The number of biopsied lesions and the positive predictive value (PPV) of each BI-RADS category during the study period are presented in Table 1 . BI-RADS category 3 and 4a lesions comprised 75.7% of all biopsied cases during the study.
Among the 735 breast cancers in 718 patients that were initially assessed as BI-RADS category 3 or 4a by US-guided core needle biopsy, the following cases were excluded: 175 ductal carcinomas in situ in 163 patients, 4 breast cancers in 4 men, 82 cancers in 82 patients due to unavailable immunohistochemical profiles, and 30 cancers in 30 patients due to unavailable fluorescence in situ hybridization data. Finally, 444 breast cancers in 439 patients were included in the final study group. Among these 439 patients, 5 had 2 lesions (Figure 1 ).
Image Evaluation and Image-Guided Biopsy B-mode US was performed with a 5-15-MHz linear transducer (HDI 5000 or 3000 or iU22; Philips Healthcare, Bothell, WA; or LOGIQ 9 or LOGIQ E9; GE Healthcare, Milwaukee, WI) by 31 board-certified radiologists dedicated to breast imaging with 1 to 21 years of experience. When performing B-mode US, the radiologist assessed the lesion size and lesion features, including composition, shape, margin, echogenicity, orientation, boundary, calcification, and posterior features, and the radiologist categorized the lesion according to the BI-RADS. 16 Ultrasound-guided core needle biopsy was performed with an automated gun (Pro-Mag 2.2; Manan Medical Products, Northbrook, IL), a 14-gauge Tru-Cut needle with a 22-mm throw (SACN biopsy needle; Medical Device Technologies, Gainesville, FL), or a 14-gauge dual-action semiautomatic core biopsy needle with a 22-mm throw (Stericut coaxial; TSK Laboratory, Tochigi, Japan), and at least 5 cores were retrieved.
Clinicopathologic Data
Medical records were reviewed for the medical history or symptoms. Pathologic reports were also reviewed to determine the histologic type, estrogen receptor (ER) or progesterone receptor (PR) status, and HER2 status. The histologic type was categorized as invasive carcinoma of no special type, invasive ductal carcinoma, special type, or invasive lobular carcinoma. 22 Breast cancers were considered ER or PR positive, if more than 1% of tumor nuclei were positive for ER or PR. 3 They were considered HER2 positive when specimens had HER2 staining scores of 3 1 or 2 1 with a fluorescence in situ 
Results
The mean age 6 SD of the 439 patients was 49.7 6 11.1 years (range, 22-79 years). The mean lesion size was 12.6 6 9.6 mm (range, 2-100 mm). Among the 439 patients, 35 (8.0%) had a first-degree relative with a history of breast cancer, and 40 (9.1%) had a personal history of breast cancer. Among the 444 breast cancers, examinations were performed for screening purposes in 199 cases (44.8%) and diagnostic purposes in 245 (55.2%). Surgery was performed on 410 cancers (92.3%), with total mastectomy being performed for 169 cancers and partial mastectomy being performed for 241. Surgery was not performed on 34 cancers because of an advanced stage (n 5 12), referral to another hospital or follow-up loss (n 5 17), death or other comorbidities (n 5 2), and neoadjuvant chemotherapy (n 5 3).
Among 444 invasive breast cancers, 15 (3.4%) were assessed as BI-RADS category 3, and 429 (96.6%) were assessed as BI-RADS category 4a on US. Biopsies of 15 BI-RADS category 3 lesions were performed for palpability (n 5 8), patients' request (n 5 3), growing or newly developed lesions (n 5 2), enhancement on abdominal computed tomography (n 5 1), and concurrent axillary lymph node enlargement (n 5 1). BI-RADS category 4a lesions were detected incidentally on screening (n 5 195), due to symptoms (n 5 146), on preoperative evaluations of other breast proven malignancy (n 5 83), and due to abnormalities on other imaging modalities (n 5 5). Histologic types of breast cancers according to intrinsic subtypes are summarized in Table  2 . Invasive carcinoma of no special type comprised 81.1% of the entire study group and was the most common histologic type. The luminal type made up 297 cases (66.9%), the HER2 type 63 (14.2%), and the triple-negative type 84 (18.9%). The mean age did not significantly differ according to the intrinsic subtype (P 5 .306). The luminal type had a significantly smaller tumor size (11.4 6 7.7 mm) than the HER2 or triplenegative type (15.8 6 15.8 and 14.3 6 9.0 mm, respectively; P < .001).
A total of 247 cancers (55.6%) cancers 10 mm or smaller, and 197 (44.4%) were larger than 10 mm (Table 3 ). The mean age was significantly older in patients with tumors of 10 or smaller mm than those larger than 10 mm. There was no difference in the frequencies of BI-RADS category 3 or 4a lesions according to the size criteria. The overall frequencies of the intrinsic breast cancer subtypes were significantly different in tumors classified by the size criteria of 10 mm. The luminal type was more frequently present in tumors of 10 mm or smaller than those larger than 10 mm ( Figure  2 ). No significant difference was noted in the frequency of the HER2 type between tumors of 10 mm or smaller and those larger than 10 mm. The triple-negative type was more frequently present in tumors larger than 10 mm (Figure 3 ). The frequencies of the histologic types were significantly different according to the size criterion of 10 mm. The special type of invasive ductal carcinoma was more frequently observed in tumors larger than 10 mm.
Discussion
In this study, we investigated whether the intrinsic subtypes of breast cancers initially assessed as BI-RADS category 3 or 4a on US differed according to tumor size. The intrinsic subtypes of breast cancers differed according to tumor size, as the luminal type was more frequently found in tumors of 10 mm or smaller than those larger than 10 mm, whereas the triple-negative type was more frequently found in tumors larger than 10 mm.
Before investigating the breast lesions assessed as BI-RADS category 3 or 4a, we evaluated the PPV of each BI-RADS category to confirm the validity of our data by seeing whether the PPV of each category was within BI-RADS recommendations. BI-RADS category 3 lesions comprised 17.4% and category 4a lesions comprised 58.3% of all biopsied cases in this study. The PPVs of category 3 and 4a lesions were within the recommended ranges of the BI-RADS, which states that the PPV of category 3 should be greater than 0% but 2% or less, and the PPV of 4a should be greater than 2% to 10%. 16 The PPVs of other categories, including 4b, 4c, and 5, in our institution were also within the ranges recommended by BI-RADS. 16 Although each BI-RADS lexicon is descriptive and specific, making a final assessment is rather subjective and comprehensive. Therefore, the validity of each institution's diagnostic performance can be an issue of concern. However, the data in our institution had PPVs within the recommended BI-RADS ranges; thus, our results can be considered valid. Although the management of BI-RADS 3 lesions is recommended as follow-up after 6 months, 16 15 breast cancers with an initial assessment of BI-RADS 3 underwent biopsies in our institution because of patients' symptoms or requests or additional findings such as growing lesions, other image abnormalities, and concurrent axillary lymph node enlargement.
Invasive carcinoma of no special type comprised 81.1% of the study cases and the prevalence rates of invasive ductal carcinoma of a special type or invasive lobular carcinoma were 11.7% and 7.2%, respectively, which were similar to previously reported percentages. 23 Invasive carcinoma of no special type was the most common histologic type observed among all 3 intrinsic subtypes. Invasive lobular carcinoma comprised 10.1% of luminal breast cancers, and most of the invasive lobular carcinomas were the luminal type, a result similar to other studies, whereas the triple-negative type was not observed. 23, 24 Breast cancers with more benign features on US showed similar prevalence rates of histologic and intrinsic subtypes with general breast cancers. 23, 24 When breast cancers were categorized according to tumor size, the special type of invasive ductal carcinoma was more frequently observed in tumors larger than 10 mm. Most (92.3%) special-type invasive ductal carcinomas in this study were either papillary or mucinous carcinomas, which present with relatively benign-like US features 25, 26 ; thus, there could be a delay in diagnosis. In this study, the mean age was significantly older in patients with tumors of 10 mm or smaller than in patients with tumors larger than 10 mm. The population in this study was selected with specific imaging criteria; therefore, a direct comparison to other studies is not possible; however, in one study with all invasive breast cancers, younger patients had larger tumors than older patients, and that finding might explain the results of our study. 27 The mean size of the luminal type was significantly smaller than that of the HER2 and triple-negative types. The luminal type was more frequently present in tumors of 10 or smaller than those larger than 10 mm, and the triple-negative type was more frequently present in tumors larger than 10 mm. According to previous literature, the triple-negative type is more frequently observed in larger breast cancers, although these previous studies did not directly analyze the prevalence of subtypes as our study did. 9, 11, 20, 21 In this study, we only included breast cancers with low suspicion or probably benign US features, and we found that there were differences in the prevalence of intrinsic subtypes according to tumor size.
Size is one of the most important prognostic factors for breast cancer, and larger tumors have a poorer prognosis than smaller tumors. [18] [19] [20] In this study, the triplenegative type was more frequently observed in breast cancers larger than 10 mm. One reason for this finding could be that triple-negative breast cancer shows relatively benign US features compared to the other subtypes. 5, 13, 17 Furthermore, the triple-negative type had a shorter doubling time than the other subtypes, 21 and this factor could also have affected our results. The triple-negative subtype is known for a poorer prognosis and more aggressive clinical behavior than the luminal type. 6, 7 Thus, tumors larger than 10 mm need to be managed with caution even when the US features of the tumors seem less suspicious.
We acknowledge that there were several limitations in this study. First, our study was of a retrospective design; therefore, a selection bias was inevitable. Second, the BI-RADS category is dependent on the subjective judgment of radiologists, and as various radiologists were involved in this study because of the relatively long study period, a bias might have existed. However, through weekly conferences and audits performed every 6 months, the radiologists in our institution tried to maintain an objective perspective when interpreting US images. Third, we correlated tumor size at the time of diagnosis with the intrinsic subtype without reviewing previous studies. Therefore, several confounding factors, such as the speed of tumor growth and the time the tumor was in the breast, that might have influenced tumor size at the time of diagnosis were not considered.
In conclusion, breast cancers assessed as BI-RADS category 3 or 4a had differing intrinsic subtypes according to tumor size, as the luminal type was more frequently present in tumors of 10 mm or smaller than those larger than 10 mm, whereas the triple-negative type was more frequently present in tumors larger than 10 mm.
